IQV

Business profile & competitive position

IQVIA Holdings Inc. operates in the Healthcare sector, specifically the Medical – Diagnostics & Research industry. In plain terms, it is a contract research, data analytics, and commercial-intelligence partner to life-sciences and healthcare organizations. Its business runs through three historically reported segments — Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions — built around proprietary health data, advanced analytics, healthcare-grade AI, and what the company calls IQVIA Connected Intelligence.

The scale of that data foundation is a core part of its identity: more than 1.2 billion unique non-identified patient records, roughly 68 petabytes of proprietary data from about 150,000 data suppliers, and information covering approximately 90% of 2024 global pharmaceutical sales. The firm also reports approximately 93,000 employees across more than 100 countries and serves over 10,000 clients, with no single client accounting for 10% or more of total revenues in 2023, 2024, or 2025.

Profitability metrics help frame the competitive position. A net margin of 8.1% is moderate — consistent with a services-heavy, human-capital business rather than a high-margin asset-light software pure-play — while a return on equity of 21.8% is materially above the cost-of-equity threshold many investors use. That combination points to a moat built less on raw price power and more on durable client relationships, hard-to-replicate data assets, global scale, and the integration of trial execution with commercial analytics.

Financial posture

As of the current snapshot, IQVIA carries a $42.6 billion market capitalization, trades near $258.44, and posts a price-to-earnings ratio of 31.1. A P/E of 31.1 sits well above broad-market averages, implying that investors are pricing in above-average earnings growth or assigning scarcity value to its data-and-services franchise. Net margin is 8.1% and ROE is 21.8%, so the valuation is not being driven by razor-thin profitability; the company is converting equity into earnings at a healthy clip.

The stock’s beta is 1.17, which means it has historically moved slightly more than the overall market on a percentage basis. Near-term technical context includes an RSI of 41.8 and a 50-day exponential moving average of $260.97, with price currently just below that average. Those are descriptive markers only, not directional signals, but they frame the stock as neither overbought nor far above near-term trend.

Strategic priorities & outlook

IQVIA’s most recent 10-K filing lays out a strategy centered on its Connected Intelligence platform: combining information, advanced analytics, transformative technology, and deep domain expertise to optimize clinical trials, real-world evidence studies, and SaaS platforms. The company explicitly wants to build on long-standing client relationships and its global footprint by knitting together R&D services and commercial services so that it becomes a more complete partner for life-sciences clients.

Beyond traditional pharma, IQVIA aims to expand penetration to a broader set of healthcare stakeholders, including payers, providers, governments, and non-governmental organizations. It also plans to grow through strategic acquisitions that strengthen its value proposition. Operationally, the firm reorganized its reportable segments effective January 1, 2026, into Commercial Solutions and Research & Development Solutions, simplifying the external reporting structure even as the underlying business remains a blend of data, analytics, and clinical/commercial services.

Macro & geopolitical exposure

As a Healthcare / Medical – Diagnostics & Research company, IQVIA’s revenue is indirectly tied to global biopharma R&D spending and clinical-trial activity. When biotech and pharmaceutical companies cut development budgets, demand for contract research, trials, and commercial analytics softens; when R&D pipelines expand, activity levels rise.

The industry is also exposed to regulatory frameworks, including data-privacy rules such as GDPR in Europe and HIPAA and related state privacy laws in the U.S. Any tightening of rules around de-identified patient data could affect how IQVIA collects, links, and monetizes its data assets. Currency is another macro factor: with operations in more than 100 countries, revenue and reported earnings can move with the U.S. dollar. Trade policy and tariffs are generally less central for a services- and data-based business than for manufacturers, but cross-border data-transfer restrictions could matter. Finally, broader healthcare policy — drug-pricing legislation, government spending on public health, and FDA review processes — can shift the pace and composition of clinical development.

Recent developments

Recent headlines include a mix of third-quarter portfolio commentary, momentum analysis, and institutional buying activity:

• On October 29, 2026, Seeking Alpha published the Artisan Global Value Fund Q3 2026 Portfolio Discussion, which included IQVIA in its broader value-oriented portfolio conversation.
• Also on October 29, 2026, Zacks ran Here's Why IQVIA Holdings (IQV) is a Strong Momentum Stock, highlighting quantitative momentum characteristics reflected in the recent price action.
• On October 28, 2026, Defense World reported that Citizens Financial Group Inc. Rhode Island purchased IQVIA Holdings Inc. ($IQV) stock, reflecting continued institutional accumulation.
• On October 27, 2026, MarketBeat published What IQVIA (IQV) Said on Its Q3 Earnings Call, summarizing management’s messaging after the most recent quarterly release.

That October 27, 2026 report came on the same day as the company’s most recent earnings release, when IQVIA reported actual EPS of $3.34 against an estimate of $3.26.

Earnings behavior & post-earnings drift

IQVIA’s earnings track record over the last eight reported quarters is a clean sweep: 8 out of 8 beats, or a 100% beat rate, with an average earnings surprise of 1.9%. That suggests the company has consistently guided the market’s real expectation to a level it can exceed.

Nevertheless, the post-earnings price behavior has been weak. The average 5-day price move in the five trading days after earnings across those eight quarters is -4.51%, classified as a downward drift. In other words, the stock has reliably beaten the estimate but has tended to fade after doing so.

The most recent quarters illustrate the pattern. On October 27, 2026, IQVIA beat by 2.5% ($3.34 vs. $3.26) and rose 2.76% the next day, with a 0% change over the following five days. On July 28, 2026, a 4.0% beat ($3.15 vs. $3.03) produced a 1.9% next-day gain but a -6.07% slide over the next five days. On May 5, 2026, a 2.8% beat ($2.90 vs. $2.82) led to a flat next-day reaction (+0.03%) and a -0.77% five-day drift. And on February 5, 2026, a narrow 0.6% beat ($3.42 vs. $3.40) produced a 3.61% next-day rally but a -6.69% five-day decline.

Looking ahead, IQVIA is scheduled to report again on February 4, 2027, before the market opens, with a current consensus EPS estimate of $3.60.

For a deeper dive into how institutional analysts and the broader sell-side are positioned around IQVIA ahead of the February 2027 report, review the full institutional verdict on the ticker page.